Soochow University Laboratory of Cancer Molecular Genetics, Department of Hematology, Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
DNA Cell Biol. 2011 Oct;30(10):777-82. doi: 10.1089/dna.2011.1223. Epub 2011 Apr 10.
Recent findings suggest that CD14 may play a role in tumor development. Previous case-control studies have revealed that CD14 -260C/T and -651 C/T polymorphisms contribute to the risk of human diseases. However, the relationship between these two functional polymorphisms and susceptibility to acute lymphoblastic leukemia (ALL) has not been explored. In this study, we performed a case-control study in a Chinese population. We found that an increased risk of ALL was associated with the -260 TT (odds ratio [OR]=1.85, 95% confidence interval [CI]=1.26-2.63) genotype compared with the CT or CC genotype. No significant association was found between -651 CC genotype and ALL (OR=1.13, 95% CI=0.77-1.69). Moreover, the increased risk was only associated with the -260 TT genotype in B-ALL (OR=1.99, 95% CI=1.34-3.01) but not in T-ALL (OR=1.48, 95% CI=0.79-2.84). The findings suggest that CD14-260C/T polymorphism can contribute to B-ALL risk in a Chinese population.
最近的研究结果表明，CD14 可能在肿瘤的发展中发挥作用。先前的病例对照研究表明，CD14-260C/T 和-651C/T 多态性与人类疾病的风险有关。然而，这两种功能性多态性与急性淋巴细胞白血病（ALL）易感性之间的关系尚未被探索。在这项研究中，我们在中国人群中进行了病例对照研究。我们发现与 CT 或 CC 基因型相比，-260TT 基因型（比值比[OR]=1.85，95%置信区间[CI]=1.26-2.63）与 ALL 的风险增加相关。-651CC 基因型与 ALL 之间没有显著相关性（OR=1.13，95%CI=0.77-1.69）。此外，这种增加的风险仅与 B-ALL 中的-260TT 基因型相关（OR=1.99，95%CI=1.34-3.01），而与 T-ALL 无关（OR=1.48，95%CI=0.79-2.84）。这些结果表明，CD14-260C/T 多态性可能导致中国人群的 B-ALL 风险增加。
